DDInter1570 DDInter1676
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ranolazine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Ranolazine {u} (Compound) causes {v} (Side Effect) Underweight
Ranolazine (Compound) resembles Guaifenesin (Compound)
Ranolazine (Compound) resembles Bupivacaine (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene)
Ranolazine (Compound) upregulates DENND2D (Gene)
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ranolazine (Compound) downregulates ATP6V1D (Gene)
Ranolazine (Compound) causes Underweight (Side Effect)